Latest Manufacturing News

Papyrus Australia has taken a significant step towards commercialisation with a $4.2 million supply contract and the near completion of its Adelaide Rapid Prototyping and R&D Facility.

RooLife Group Limited (ASX, RLG) reported a strong Q2 FY2026 with revenue climbing to $3.25 million, driven by rapid growth in its RLG Coffee range in China. The company’s lean, data-driven marketplace model is scaling efficiently despite expected seasonal slowdowns.

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

Imugene Limited has reported compelling clinical trial results for its off-the-shelf CAR T therapy, azer-cel, alongside FDA validation and a strategic collaboration, while managing cash flow amid cost reductions.

Volt Group Limited has reported record full-year revenue for CY25, bolstered by the strategic acquisition of digital inspection firm 4D Delta and strong performances across its mining technology businesses.

Green360 Technologies has made significant strides in commercialising its low-carbon cement product Eco-Clay, delivering successful large-scale trials and securing a robust financial footing heading into 2026.

Terragen Holdings reports a strong quarter with an 87% increase in sales of its ruminant probiotic and advances key livestock and crop trials, positioning itself for expanded market access.

Alexium International Group has acquired Microtek Laboratories’ microencapsulation business, marking a strategic pivot to manufacturing-led growth and raising $4.6 million to fund expansion. Despite a slight sales dip, the company is poised for a stronger 2026 with new product lines and military trials underway.

Holista Colltech has reported a positive operating cash flow for the December quarter, driven by disciplined cost management and a successful capital raise, despite softer sales and ongoing legal disputes.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Alpha HPA Limited has successfully raised A$225 million through a fully underwritten equity placement, bolstered by strong institutional support, to fund the next phase of its high purity alumina project. This capital injection, combined with existing cash and government funding, positions the company to advance its Stage 2 construction and expand Stage 1 capacity.

Evion Group gains momentum as the US-Africa Strategic Infrastructure and Investment Working Group fosters trade, Madagascar accelerates mining permits, and Indian graphite operations deliver strong sales.